Toxins 2012, 4(11), 1058-1081; doi:10.3390/toxins4111058
Article

Comparative Antitumor Effect of Preventive versus Therapeutic Vaccines Employing B16 Melanoma Cells Genetically Modified to Express GM-CSF and B7.2 in a Murine Model

1 Department of Pharmacology, Faculty of Medicine, University of Valencia, Avda. Blasco Ibáñez, 15, Valencia 46010, Spain 2 Instituto Investigación Sanitaria La Fe, Bulevar Sur s/n, Valencia 46026, Spain 3 Dermatology, Hospital Universitario y Politécnico La Fe, Bulevar Sur s/n, Valencia 46026, Spain 4 Radiotherapy, Hospital Clínico Universitario, Av. Blasco Ibáñez, 10, Valencia 46010, Spain 5 Clinical Pharmacology Unit, Hospital Universitario y Politécnico La Fe, Bulevar Sur s/n, Valencia 46026, Spain
* Authors to whom correspondence should be addressed.
Received: 11 July 2012; in revised form: 24 September 2012 / Accepted: 18 October 2012 / Published: 31 October 2012
(This article belongs to the Special Issue Toxicity and Therapeutic Interventions in the Immune System)
PDF Full-text Download PDF Full-Text [1022 KB, uploaded 31 October 2012 09:18 CET]
Abstract: Cancer vaccines have always been a subject of gene therapy research. One of the most successful approaches has been working with genetically modified tumor cells. In this study, we describe our approach to achieving an immune response against a murine melanoma model, employing B16 tumor cells expressing GM-CSF and B7.2. Wild B16 cells were injected in C57BL6 mice to cause the tumor. Irradiated B16 cells transfected with GM-CSF, B7.2, or both, were processed as a preventive and therapeutic vaccination. Tumor volumes were measured and survival curves were obtained. Blood samples were taken from mice, and IgGs of each treatment group were also measured. The regulatory T cells (Treg) of selected groups were quantified using counts of images taken by confocal microscopy. Results: one hundred percent survival was achieved by preventive vaccination with the group of cells transfected with p2F_GM-CSF. Therapeutic vaccination achieved initial inhibition of tumor growth but did not secure overall survival of the animals. Classical Treg cells did not vary among the different groups in this therapeutic vaccination model.
Keywords: cancer vaccines; gene therapy; non-viral; GM-CSF; B7.2

Article Statistics

Load and display the download statistics.

Citations to this Article

Cite This Article

MDPI and ACS Style

Miguel, A.; Herrero, M.J.; Sendra, L.; Botella, R.; Algás, R.; Sánchez, M.; Aliño, S.F. Comparative Antitumor Effect of Preventive versus Therapeutic Vaccines Employing B16 Melanoma Cells Genetically Modified to Express GM-CSF and B7.2 in a Murine Model. Toxins 2012, 4, 1058-1081.

AMA Style

Miguel A, Herrero MJ, Sendra L, Botella R, Algás R, Sánchez M, Aliño SF. Comparative Antitumor Effect of Preventive versus Therapeutic Vaccines Employing B16 Melanoma Cells Genetically Modified to Express GM-CSF and B7.2 in a Murine Model. Toxins. 2012; 4(11):1058-1081.

Chicago/Turabian Style

Miguel, Antonio; Herrero, María J.; Sendra, Luis; Botella, Rafael; Algás, Rosa; Sánchez, Maria; Aliño, Salvador F. 2012. "Comparative Antitumor Effect of Preventive versus Therapeutic Vaccines Employing B16 Melanoma Cells Genetically Modified to Express GM-CSF and B7.2 in a Murine Model." Toxins 4, no. 11: 1058-1081.

Toxins EISSN 2072-6651 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert